Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Publication year range
1.
Eur J Clin Pharmacol ; 60(10): 703-8, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15619133

ABSTRACT

OBJECTIVE: The inter-individual variability of cyclosporine (CsA) pharmacokinetics is well known. However, there is obviously also an inter-individual pharmacodynamic variability, which might be explored by the measurement of biomarkers of CsA effects. METHODS: In 11 renal transplant patients, blood CsA concentrations, calcineurin inhibition in peripheral blood mononuclear cells and endothelin plasma concentrations were measured over a 4-h period after CsA intake. RESULTS: Mean plasma endothelin concentrations were higher than those of healthy subjects (3.66+/-0.46 pg ml(-1) versus 3.15+/-0.40 pg ml(-1), P<0.01) but were not related to CsA dose or blood concentrations. There was a linear relationship between calcineurin inhibition at t (0) and mean endothelin concentrations (r (2)=0.51, P<0.05). Patients with gingival hypertrophy had higher mean endothelin concentrations than patients without this complication (4.0 pg ml(-1) versus 3.4 pg ml(-1), P<0.01), although CsA doses and concentrations were not different between these two groups. CONCLUSION: We observed a correlation between calcineurin inhibition and endothelin concentrations. Endothelin plasma concentrations is a biomarker of CsA effect, which may provide more information than CsA blood concentrations.


Subject(s)
Calcineurin Inhibitors , Cyclosporine/blood , Cyclosporine/pharmacology , Endothelins/blood , Immunosuppressive Agents/pharmacology , Kidney Transplantation , Adult , Aged , Blood Pressure/drug effects , Calcineurin/blood , Chromatography, High Pressure Liquid , Cyclosporine/adverse effects , Female , Gingival Hypertrophy/chemically induced , Humans , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/blood , Male , Middle Aged
2.
Eur J Clin Pharmacol ; 58(8): 507-13, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12451427

ABSTRACT

OBJECTIVES: We conducted a population pharmacokinetic analysis of cisapride in neonates to study whether metabolic immaturity in this population may lead to increased concentrations. METHODS: Cisapride was administered orally in 91 neonates at the dose of 0.2 mg/kg four times a day. Plasma concentrations were measured using a validated HPLC method. A one-compartment model with first-order absorption was fitted to the data using NONMEM software. RESULTS: One to seven plasma samples were obtained from neonates aged 7-123 days. Cisapride concentrations ranged from 5.5 ng/mL to 172 ng/mL and were not higher than those reported in adults. The absorption constant rate was fixed to 2.5 h-1. Clearance (CL/F) and volume of distribution (V/F) both significantly correlated to weight (WT), but addition of this covariate in V/F did not improve the objective function after it was added in the CL/F covariate model. Prematurity, postnatal age, or coadministered drugs did not affect cisapride clearance. Final population pharmacokinetic parameters (interindividual variability) were: V/F=17,200 mL (90.4%) and CL/F=3.91 x WT(3/4) mL/h (36.3%). CONCLUSIONS: Our finding that cisapride clearance is primarily influenced by weight is in agreement with current recommendations of weight-adjusted doses. This study indicates that no clinically relevant maturational changes in cisapride clearance have to be considered during the first quadrimester of life.


Subject(s)
Cisapride/blood , Infant, Newborn/metabolism , Cisapride/administration & dosage , Cisapride/adverse effects , Female , Humans , Male , Metabolic Clearance Rate , Models, Biological , Prospective Studies
3.
Therapie ; 56(5): 519-24, 2001.
Article in English | MEDLINE | ID: mdl-11806288

ABSTRACT

Until recently, only compassionate use of ciprofloxacin in children with cystic fibrosis was possible despite limited pharmacokinetic data. We studied five subjects with cystic fibrosis and exacerbation of pulmonary infection. A 15 mg/kg b.i.d. regimen of oral ciprofloxacin was administered. On the 15th day, eight blood samples were collected and plasma concentrations were measured by HPLC. The actual dose administered ranged from 10 to 14 mg/kg b.i.d., due to the fixed-dosage formulation. Corresponding AUC0-12 ranged from 8.2 to 11.9 mg.h/L. Plasma concentrations were maintained above individual MICs for a median time of 12.7 h over 24 h. The median area under the inhibitory curve was 52.8, which is about half the proposed target value for ciprofloxacin in pulmonary infections with Gram-negative bacteria such as Pseudomonas aeruginosa. A higher dose, administered from a specific formulation to ensure precise dosing, must be given in order to obtain adequate concentrations in cystic fibrosis children.


Subject(s)
Anti-Infective Agents/pharmacokinetics , Ciprofloxacin/pharmacokinetics , Cystic Fibrosis/complications , Administration, Oral , Adolescent , Adult , Anti-Infective Agents/administration & dosage , Anti-Infective Agents/therapeutic use , Child , Ciprofloxacin/administration & dosage , Ciprofloxacin/blood , Ciprofloxacin/therapeutic use , Cystic Fibrosis/blood , Female , Humans , Male , Metabolic Clearance Rate , Pseudomonas Infections/drug therapy
4.
Therapie ; 56(6): 663-8, 2001.
Article in French | MEDLINE | ID: mdl-11878088

ABSTRACT

Pharmacokinetic studies in neonates are essential because of maturational changes in physiological functions during this period. International harmonization conferences have established guidelines for such studies, including recommendations on age ranges to be studied and description of methods and study design. Multiple blood sampling to obtain a full pharmacokinetic profile cannot be proposed in neonates. Population pharmacokinetic analysis, with minimal sampling schemes, is more appropriate but involves more subjects than the traditional approach. Population pharmacokinetic analysis also focuses on the influence of individual factors on pharmacokinetic parameters. Most studies performed with neonates have involved drugs with a narrow safety margin and cleared by renal or metabolic routes to study the impact of immaturity on drug concentrations and on clinical effects.


Subject(s)
Infant, Newborn/metabolism , Neonatology , Pharmacokinetics , Humans
5.
Fundam Clin Pharmacol ; 13(5): 595-604, 1999.
Article in English | MEDLINE | ID: mdl-10520733

ABSTRACT

High-dose methotrexate (HD-MTX) with leucovorin rescue is a component of therapy in children with acute lymphoblastic leukaemia. Since MTX toxicity is related to drug exposure, a monitoring of serum MTX concentrations at H24, H48, H72 and until the concentration is less than 0.2 micromol/L is commonly performed. However, a number of patients may reach concentrations of less than 0.2 micromol/L long before the next sampling is scheduled. The aim of our study was to develop a Bayesian method predicting the time at which MTX concentration reaches 0.2 micromol/L in order to decrease the number of samples drawn and to allow for a more rapid patient discharge. Methotrexate population parameters were estimated from a retrospective analysis of 60 infusions in 23 children and MTX concentrations were predicted from an independent set of 20 courses in 14 children with a Bayesian approach using either one (H48) or two (H24 and H48) samples. The following population parameters were obtained using a two-compartment model: CL = 3.51 L/h (inter-individual variability: 66%), Vd = 8.67 L (58%), k12 = 0.0044 h(-1)(105%), k21 = 0.039 h(-1)(25%). Clearance and Vd were found to increase with weight and age respectively. Both sampling schedules tested for the Bayesian estimation enabled accurate prediction of concentrations and provided satisfactory precision despite a small bias. When considering the ability to predict the time at which the threshold was reached, the one-sample (H48) schedule gave the best results. We conclude that a sampling schedule involving only one sample and Bayesian parameter estimation may be able to predict the delay necessary to reach 0.2 micromol/L in each individual.


Subject(s)
Antimetabolites, Antineoplastic/pharmacokinetics , Methotrexate/pharmacokinetics , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Adolescent , Antimetabolites, Antineoplastic/blood , Bayes Theorem , Child , Child, Preschool , Dose-Response Relationship, Drug , Female , Humans , Infant , Infusions, Intravenous , Male , Metabolic Clearance Rate , Methotrexate/blood , Randomized Controlled Trials as Topic , Retrospective Studies , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...